NAVB - Navidea Biopharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
Annual

Cash Flow

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Cash flows from operating activities
Net Income
-11,337
-16,126
74,946
-14,308
Depreciation & amortization
145
150
255
501
Deferred income taxes
-
-
-
-
Stock based compensation
224
307
394
278
Change in working capital
847
13,835
-25,190
13,105
Accounts receivable
-
12,926
-
-
Inventory
-
0
1,471
-861
Accounts Payable
223
-430
-6,018
5,441
Other working capital
-8,776
4,229
59,050
3,555
Other non-cash items
344
806
4,036
4,700
Net cash provided by operating activites
-8,749
4,275
59,084
3,557
Cash flows from investing activities
Investments in property, plant and equipment
-
-46
-34
-2
Acquisitions, net
-
-
-
-
Purchases of investments
-400
-600
-2,200
-
Sales/Maturities of investments
1,200
1,600
400
28
Other investing activites
-
-
-
-110
Net cash used for investing activites
802
954
-1,834
-39
Cash flows from financing activities
Debt repayment
-393
-396
-59,754
-234
Common stock issued
6,047
3,000
72
-
Common stock repurchased
-
-
-
-
Dividends Paid
-
-
-
-
Other financing activites
-572
-7,153
3,687
-8,925
Net cash used privided by (used for) financing activities
5,081
-4,548
-55,994
-9,144
Net change in cash
-2,866
681
1,256
-5,627
Cash at beginning of period
5,707
2,795
1,539
7,166
Cash at end of period
2,841
3,476
2,795
1,539
Free Cash Flow
Operating Cash Flow
-8,749
4,275
59,084
3,557
Capital Expenditure
-
-46
-34
-2
Free Cash Flow
-8,776
4,229
59,050
3,555